Scotiabank Remains a Buy on AbbVie (ABBV)

AbbVie (ABBV) presented Phase 3 AFFIRM trial data at the American College of Gastroenterology 2026 Annual Scientific Meeting, showing subcutaneous Skyrizi achieved 35.8% endoscopic remission in Crohn's patients at Week 24, compared to 9.1% for placebo. The drug is under regulatory review. ABBV closed at $274.36, down 2.40%.

AbbVie reported Phase 3 AFFIRM data showing subcutaneous Skyrizi achieved 35.8% endoscopic remission in Crohn's patients at Week 24, surpassing placebo. The trial involved 289 adults, with co-primary endpoints met at Week 12. Results were presented at a gastroenterology conference. ABBV stock closed at $274.36, down 2.40%.

AbbVie (ABBV) reported positive phase 3 trial results for Skyrizi in treating Crohn's disease, showing remission and ulcer healing rates. The company has submitted regulatory applications. ABBV offers a 2.49% dividend yield with an 85% payout ratio and a 5.2% 3-year dividend growth rate. The stock is 23.5% above its GF Value, indicating modest overvaluation. ABBV has a GF Score of 76, reflecting strong profitability but valuation and momentum challenges.

AbbVie reported phase 3 trial results showing its injectable Skyrizi formulation achieved higher endoscopic remission rates in Crohn's patients than placebo. The data, presented at a medical conference, may support future regulatory filings. According to the company, the results demonstrate the potential of subcutaneous Skyrizi as a treatment option. Financial details were not disclosed. (ABBV).

Abbvie reported positive results from its Phase 3 trial of Skyrizi for Crohn's disease, with 36% of patients achieving endoscopic remission. The study showed higher efficacy in advanced therapy-naive patients. Skyrizi is under regulatory review by the FDA and EMA for subcutaneous induction in adults with Crohn's disease, according to the company.

AbbVie presented Phase 3 AFFIRM study results showing SKYRIZI® (risankizumab-rzaa) achieved higher rates of endoscopic remission and ulcer-free endoscopy in Crohn's disease patients compared to placebo. The data support FDA approval for subcutaneous induction dosing. SKYRIZI is already approved for other immune-mediated diseases.